Reasons to attend

The biopharma market is experiencing solid growth, with revenue projected to reach USD 516 billion in 2024, driven by the prevalence of chronic diseases and an increasing demand for innovative treatments. M&A activity saw a significant rebound in 2023, up $140 billion.

Join us for this webinar as our experts provide a comprehensive understanding of how clinical trial outcomes impact company valuations, particularly focusing on emerging biopharma companies. The speakers will explore the underlying drivers of these impacts, such as trial results compared to investors’ prior expectations, development phase at readout, therapy area, and trial design.

Key discussion points will include:

• The asymmetry of market response to clinical trial results
• The role of therapy areas, trial designs, and company size in driving valuation impact
• Practical implications of understanding these drivers of value inflection for management teams
• The importance of biopharma’s delivering the right clinical data at critical inflection points in the development path to maximize value for investors

Don’t miss out on these valuable insights to help you navigate the complex landscape of biopharma valuations.

Register now to secure your spot.

Speakers:

Catherine Beech OBE
CEO, Exonate

Amir Hefni
CEO, Resolution Therapeutics

William Harries
Life Sciences Senior Consultant, EMEA Thought Leadership, IQVIA

Joe Hopcraft
Senior Client Partner, IQVIA